CPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Catalyst Pharmaceuticals's Enterprise Value is $1,538.0 Mil. Catalyst Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $78.3 Mil. Therefore, Catalyst Pharmaceuticals's EV-to-EBIT ratio for today is 19.64.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Catalyst Pharmaceuticals's Enterprise Value is $1,538.0 Mil. Catalyst Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $114.0 Mil. Therefore, Catalyst Pharmaceuticals's EV-to-EBITDA ratio for today is 13.49.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Catalyst Pharmaceuticals's Enterprise Value is $1,538.0 Mil. Catalyst Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $411.3 Mil. Therefore, Catalyst Pharmaceuticals's EV-to-Revenue ratio for today is 3.74.
The historical data trend for Catalyst Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 294.17 | 206.38 | 510.20 | 1,663.39 | 1,666.64 |
Catalyst Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Enterprise Value | Get a 7-Day Free Trial | 1,612.02 | 1,256.32 | 1,128.88 | 1,666.64 | 1,574.46 |
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Catalyst Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1800.72082 | + | 0 | + | 3.188 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.369 | + | 0 | - | 137.636 |
= | 1,666.6 |
Catalyst Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as
Enterprise Value (Q: Mar. 2024 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 1881.3982 | + | 0 | + | 3.091 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.377 | + | 0 | - | 310.411 |
= | 1,574.5 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (NAS:CPRX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Catalyst Pharmaceuticals's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 1538.015 | / | 78.329 | |
= | 19.64 |
Catalyst Pharmaceuticals's current Enterprise Value is $1,538.0 Mil.
Catalyst Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $78.3 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Catalyst Pharmaceuticals's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 1538.015 | / | 114.04 | |
= | 13.49 |
Catalyst Pharmaceuticals's current Enterprise Value is $1,538.0 Mil.
Catalyst Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $114.0 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Catalyst Pharmaceuticals's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 1538.015 | / | 411.347 | |
= | 3.74 |
Catalyst Pharmaceuticals's current Enterprise Value is $1,538.0 Mil.
Catalyst Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $411.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Molly Harper | director | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134 |
David S Tierney | director | C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
Alicia Grande | officer: Chief Accounting Officer | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
Gary Ingenito | officer: Chief Medical Officer | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
Steve Miller | officer: VP Development & Management | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
Tamar Thompson | director | C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037 |
Patrick J Mcenany | director, 10 percent owner, officer: President and Chief Executive | C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Carmen Jeffrey Del | officer: Chief Commercial Officer | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134 |
Brian Elsbernd | officer: Chief Compliance/Legal Officer | 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134 |
Philip H Coelho | director | C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Charles B O'keeffe | director | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
Donald A Denkhaus | director | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
Preethi Sundaram | officer: Chief Product Devel. Officer | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134 |
Daniel Brennan | officer: Chief Commercial Officer | C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286 |
M Douglas Winship | officer: V.P. of Regulatory Operations | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
From GuruFocus
By Marketwired • 10-23-2023
By Marketwired • 10-16-2023
By Akim Guerreiro • 01-18-2024
By sperokesalga sperokesalga • 06-01-2023
By GuruFocus Research • 12-15-2023
By Stock market mentor Stock market mentor • 02-07-2023
By GuruFocus Research • 12-14-2023
By sperokesalga sperokesalga • 05-30-2023
By Marketwired • 08-09-2023
By Marketwired • 11-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.